---
title: "R3 Vascular secures WCG IRB approval and CMS category B Medicare coverage for ELITE-BTK pivotal trial"
date: "2025-01-13T12:04:12.000Z"
publishedDate: "13 janvier 2025"
summary: "R3 Vascular today announced that it has received WCG Institutional Review Board (IRB) approval for the ELITE-BTK pivotal trial of its Magnitude drug-eluting next-generation bioresorbable scaffold for below-the-knee (BTK) peripheral arterial disease (PAD). This approval allows the trial to take place at institutions that utilise WCG IRB as their central IRB in the USA."
importance: ""
sourceUrl: "https://vascularnews.com/r3-vascular-secures-wcg-irb-approval-and-cms-category-b-medicare-coverage-for-elite-btk-pivotal-trial/"
tags: ["France", "Actualité", "Vascular News — Latest"]
permalink: "/papers/2025-01-13-r3-vascular-secures-wcg-irb-approval-and-cms-category-b-medicare-coverage-for-elite-btk-pivotal-trial"
imageUrl: "https://vascularnews.com/wp-content/uploads/sites/7/2020/10/R3-Vascular-logo-web.jpg"
imageCredit: "Image de l’article — droits possiblement réservés — https://vascularnews.com/r3-vascular-secures-wcg-irb-approval-and-cms-category-b-medicare-coverage-for-elite-btk-pivotal-trial/"
---

![R3 Vascular secures WCG IRB approval and CMS category B Medicare coverage for ELITE-BTK pivotal trial](https://vascularnews.com/wp-content/uploads/sites/7/2020/10/R3-Vascular-logo-web.jpg)

*Crédit image : Image de l’article — droits possiblement réservés — https://vascularnews.com/r3-vascular-secures-wcg-irb-approval-and-cms-category-b-medicare-coverage-for-elite-btk-pivotal-trial/*

## L’essentiel

R3 Vascular today announced that it has received WCG Institutional Review Board (IRB) approval for the ELITE-BTK pivotal trial of its Magnitude drug-eluting next-generation bioresorbable scaffold for below-the-knee (BTK) peripheral arterial disease (PAD). This approval allows the trial to take place at institutions that utilise WCG IRB as their central IRB in the USA.

## Lien source

https://vascularnews.com/r3-vascular-secures-wcg-irb-approval-and-cms-category-b-medicare-coverage-for-elite-btk-pivotal-trial/
